March 9, 2018 Conference


Combination therapy of Rituximab and Intravenous Immunoglobulin for Recalcitrant Ocular Cicatricial Pemphigoid

Dr. Peter Chang, Massachusetts Eye Research and Surgery Institution (MERSI) (Presenter)
C Stephen Foster, Massachusetts Eye Research and Surgery Institution
Razzaque Ahmed, Center for Blistering Diseases

Six OCP patients, 4 of whom were monocular at baseline, received RTX and IVIg infusion in a particular regimen: RTX is given at 375mg/m2 BSA weekly for 8 weeks, followed by 4 monthly infusions; IVIg at the dose of 2g/kg divided over a 3-day cycle is given immediately before the institution of RTX therapy, then given monthly for a total of 6 months, then stretched to every 6, 8, 10, 12, 14, and 16 weeks. The total follow-up after the completion of the combination therapy is 104 months (8.7 years), and all 6 patients had no progression in OCP staging and maintained baseline BCVA. No infection or death was associated with the combination therapy. B-cell data and levels of auto-antibodies to human beta-4 integrin, the latter of which correlated with OCP disease activity, will be provided in this presentation.